Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

Cencora’s fiscal Q4 2026 adjusted EPS rose 21.4% to $4.66, beating the $4.56 consensus, while revenue increased 5.5% to $88.35 billion versus $88.16 billion expected; adjusted operating margin expanded 19 basis points to 1.41%. The company forecast fiscal 2027 adjusted EPS of $19.40-$19.75, or 8%-10% growth, and raised its quarterly dividend 10% to $0.66 per share. Growth reflected specialty drug volumes, GLP-1 demand and OneOncology, though lower-margin GLP-1 sales, acquisition expenses and higher interest costs were offsets; Cencora also agreed to acquire American Oncology Network.

Analysis

The key issue is whether specialty is becoming a durable earnings engine or merely masking slower, low-margin distribution growth. In a thin-margin wholesaler, modest improvement in specialty/provider-services mix can have outsized operating-income impact; the new segment disclosures should make that mix shift easier to test, but also raise the bar for execution. Near term (days), the beat and higher dividend may support sentiment, though without valuation or positioning data there is no basis to call the reaction under- or overdone. Over 1–3 months, track organic growth separately from acquired contributions, specialty operating-income growth versus the company’s 18–21% outlook, and cash conversion against its free-cash-flow plan. Acquisition integration and financing are the main offsets: added provider exposure can deepen commercial access, but also brings execution risk and more capital demands; higher interest costs can absorb part of the operating uplift. Over 6–18 months, sustained specialty mix gains could differentiate Cencora from broadline distributors such as McKesson and Cardinal Health. The contrarian risk is that headline EPS growth overstates underlying acceleration: distribution operating-income growth is guided below specialty, while consolidated EPS growth also depends on financing, integration and capital allocation. Falsifiers include specialty operating-income growth falling short of guidance, weaker-than-planned cash generation, or further increases in net interest expense. Verify organic/acquisition contribution and deal financing before sizing a position.

Key Decisions for Investors

• Avoid chasing the immediate earnings reaction without valuation and positioning context. Treat COR as a catalyst watch: the next useful confirmation is whether specialty operating-income growth tracks the 18–21% fiscal 2027 outlook, rather than relying on consolidated EPS alone.
• Conditional pair idea for a 1–3 month horizon: modestly overweight COR versus broadline distributors such as McKesson or Cardinal Health if subsequent disclosures confirm organic specialty growth and improving cash conversion. Reduce or exit the relative position if specialty growth misses guidance or the gap is mainly acquisition-driven; compare current valuation and peer fundamentals before entry.
• Monitor quarterly cash generation, net interest expense and integration costs. A sustained shortfall versus the company’s cash-flow plan, or financing costs that constrain EPS delivery, would undermine the specialty-growth thesis and argue against adding exposure.
• Do not infer a read-through to OPKO Health, Globus Medical or Merit Medical Systems from this report; it provides no direct evidence of changes to their demand, pricing or earnings outlook.